Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Alligator Bioscience

Drug Profile

Research programme: cancer therapeutics - Alligator Bioscience

Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-CHIPS; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibody

Latest Information Update: 22 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alligator Bioscience
  • Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Bispecific antibodies; Monoclonal antibodies; Proteins
  • Mechanism of Action Complement C5a inhibitors; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Discontinued Reperfusion injury

Most Recent Events

  • 20 Aug 2019 An antibody from ALLIGATOR-GOLD® technology platform licensed to Biotheus in China, Hong Kong, Macau and Taiwan
  • 28 Jul 2018 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
  • 13 Sep 2017 Alligator Bioscience, Center for Applied Medical Research (CIMA) and Clinica Universidad de Navarra entered into research agreement to further investigate ATOR 1017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top